Introduction
transplant-ineligible, tumor
DISEASE PROGRESSION, MULTIPLE MYELOMA (MM), TUMOR
Despite treatment advances contributing to improved outcomes in patients with multiple myeloma (MM), those not eligible for autologous stem cell transplantation (ASCT) have lower survival rates partially due to receiving less-intensive therapy based on advanced age and/or comorbidities [Molecular and immunophenotypic techniques can be used to monitor MRD [Bortezomib-lenalidomide-dexamethasone (VRd) has become a standard-of-care regimen in patients with NDMM ineligible for/with no intent for immediate ASCT based on the Phase 3 SWOG S0777 study, in which VRd administered until disease progression resulted in significantly longer OS than with lenalidomide-dexamethasone (Rd) alone [Adding anti-CD38 monoclonal antibodies (eg, isatuximab) to the VRd standard-of-care regimen may provide additional options for patients. Isatuximab, an IgG1 monoclonal antibody that targets a specific epitope of CD38, has multiple tumor cell–killing mechanisms of action [This study was designed to evaluate the preliminary efficacy, safety, and pharmacokinetics of the quadruplet regimen of isatuximab combined with VRd (Isa-VRd) in transplant-ineligible patients with NDMM. In the Isa-VRd Part B cohort, patients with no intent for immediate transplant were also included.